RxDoctor Payments Data

John Mullin

Physician Assistant · Staten Island, NYNPI 1457527095

Payments from drug & device makers

$1,683in general payments, 2019–2025

Across 69 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$653
  • Johnson & Johnson$135
  • Neurocrine Biosciences, Inc.$129
  • Lundbeck LLC$99
  • AbbVie$90
  • Medtronic$87
  • plus $490 from 16 others

What the payments were for

  • Food & beverage$1,66399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,683 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$13,469
Medicare patients
42
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide44$44,600
JardianceEmpagliflozin47$36,748
MounjaroTirzepatide31$30,090
KerendiaFinerenone43$30,067
FarxigaDapagliflozin Propanediol49$27,929
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$19,242
OzempicSemaglutide15$14,067
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$13,649
JanuviaSitagliptin Phosphate20$10,833
EntrestoSacubitril/Valsartan16$10,442
Albuterol Sulfate HfaAlbuterol Sulfate300$10,347
Arnuity ElliptaFluticasone Furoate39$9,466
Breo ElliptaFluticasone/Vilanterol23$9,076
Tresiba Flextouch U-100Insulin Degludec24$7,553
Novolog FlexpenInsulin Aspart88$7,371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$19$32,89161 claims
Lilly USA, LLCMounjaro$22$30,09031 claims
BayerKerendia$20$30,06743 claims
AbbVieSynthroid$90$67415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →